Edition:
United Kingdom

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

114.61USD
18 Dec 2018
Change (% chg)

-- (--)
Prev Close
$114.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
470,170
52-wk High
$151.99
52-wk Low
$51.07

Latest Key Developments (Source: Significant Developments)

Dexcom Prices Offering Of $750.0 Mln Of 0.75% Convertible Senior Notes
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - DexCom Inc ::DEXCOM PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES.DEXCOM INC - PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES DUE 2023.  Full Article

Dexcom Announces Proposed Offering Of $750 Mln Of Convertible Senior Notes
Monday, 26 Nov 2018 

Nov 26 (Reuters) - DexCom Inc ::DEXCOM ANNOUNCES PROPOSED OFFERING OF $750 MILLION OF CONVERTIBLE SENIOR NOTES.DEXCOM - INTENDS TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2023.DEXCOM INC - INTENDS TO GRANT INITIAL PURCHASERS OF NOTES A 13-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $100 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES.  Full Article

DexCom Inc-Collaboration & License Agreement With Verily Life Sciences Shall Continue Until Dec. 31, 2028
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Alphabet Holding Company Inc [RIC:RIC:ALHC.UL]::DEXCOM INC - COLLABORATION AND LICENSE AGREEMENT WITH VERILY LIFE SCIENCES SHALL CONTINUE UNTIL DECEMBER 31, 2028.DEXCOM INC - AGREEMENT SHALL BE EXTENDED UNTIL DECEMBER 31, 2033 UPON ACHIEVEMENT OF FIRST REVENUE MILESTONE EVENT & PAYMENT BY CO TO VERILY.  Full Article

Dexcom Files For Potential Mixed Shelf Offering Size Not Disclosed
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - DexCom Inc ::DEXCOM INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED .  Full Article

Dexcom And Verily Amend Collaboration And License Agreement
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - DexCom Inc ::DEXCOM AND VERILY AMEND COLLABORATION AND LICENSE AGREEMENT.DEXCOM INC - AMENDMENT INTENDED TO REINFORCE JOINT PRODUCT DEVELOPMENT TARGETS, ACCELERATE DEXCOM'S EFFORTS IN TYPE 2 DIABETES.DEXCOM INC - ROYALTY PAYMENTS SET FORTH IN ORIGINAL AGREEMENT HAVE BEEN ELIMINATED IN AMENDED AGREEMENT.DEXCOM INC - FOCUS SHIFTS TO COMMERCIALIZING SECOND GENERATION OFFERING.DEXCOM INC - WILL MAKE AN INITIAL PAYMENT OF $250 MILLION IN SHARES OF ITS COMMON STOCK.DEXCOM INC - DEXCOM WILL NOT OWE ANY ROYALTIES PURSUANT TO TERMS OF AMENDED AGREEMENT.DEXCOM INC - DEXCOM MAY MAKE UP TO $275 MILLION OF MILESTONE PAYMENTS IN SHARES OF ITS COMMON STOCK.DEXCOM - UNDER AGREEMENT, MILESTONE PAYMENTS OF UP TO $280 MILLION MAY BECOME DUE & PAYABLE BY CO UPON ACHIEVEMENT OF FUTURE PRODUCT LAUNCH, REVENUE MILESTONES.DEXCOM INC - FOR VERILY'S ONDUO FRANCHISE, CO TO BE PREFERRED CGM DEVICE SUPPLIER INTO ONDUO'S TYPE 2 DIABETES MANAGEMENT PROGRAM.DEXCOM INC - DEXCOM AND VERILY HAVE EXPANDED OPTIONS TO COLLABORATE ON DEVELOPMENT OF ADDITIONAL PRODUCTS AND SOFTWARE PERTAINING TO DEXCOM'S PRODUCTS.  Full Article

Agamatrix Says Judge Issued Order To Dexcom To Pay Co Its Costs Defending Against Case Since August 1, 2017
Tuesday, 5 Jun 2018 

June 5 (Reuters) - DexCom Inc ::AGAMATRIX - PREVAILING OUTCOME IN RETALIATORY PATENT INFRINGEMENT LAWSUIT BROUGHT BY DEXCOM INC.AGAMATRIX - JUDGE ISSUED ORDER IN MAY ORDERING DEXCOM TO PAY AGAMATRIX ITS COSTS, ATTORNEYS' FEES, EXPENSES DEFENDING AGAINST CASE SINCE AUGUST 1, 2017.AGAMATRIX - FEES CO IS REQUESTING ARE ABOUT $1.4 MILLION.  Full Article

DexCom Says Preliminary Q4 Revenue Was $218 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - DexCom Inc ::DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK.SEES FY 2018 REVENUE ABOUT $830 MILLION TO $850 MILLION.SEES FY 2017 REVENUE ABOUT $715 MILLION.PRELIMINARY Q4 REVENUE $218 MILLION VERSUS I/B/E/S VIEW $212.6 MILLION .FY2017 REVENUE VIEW $710.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $854.6 MILLION -- THOMSON REUTERS I/B/E/S.Q4 REVENUE VIEW $212.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Dexcom announces development agreement with Lilly
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Dexcom Inc ::Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem.Says ‍companies expect to combine Lilly's smart insulin delivery devices and Dexcom CGM.  Full Article

Dexcom Inc reports Q3 GAAP loss per share $0.02
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Dexcom Inc :Dexcom, inc. Reports record third quarter 2017 financial results.Q3 non-gaap loss per share $0.04.Q3 gaap loss per share $0.02.Q3 revenue $184.6 million versus i/b/e/s view $184.2 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Tandem Diabetes Care Inc ::‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​.Tandem diabetes care inc - ‍tandem and Dexcom are now extending terms of their welcome programs for animas customers through march 31, 2018​.  Full Article

REUTERS SUMMIT-Citron's Left covered Facebook short, still bearish on Netflix

NEW YORK, Nov 12 Andrew Left has covered his short position on Facebook Inc, due to its booming Instagram business, but is still betting on a decline in Netflix Inc shares, the activist short-seller told Reuters on Monday.